Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J gets Closure

This article was originally published in The Tan Sheet

Executive Summary

Manufacturer of Band-Aid Liquid Bandage and Dermabond topical adhesive is being acquired by Johnson & Johnson in a cash-for-stock exchange worth roughly $370 mil., the firms announce March 4. Closure will operate as a stand-alone entity reporting through J&J division Ethicon. Liquid Band-Aid sales grew roughly 20% over the prior-year period due to the domestic launch of the Skin Crack Gel line extension. However, sales were negatively impacted by private-label competition. J&J will incur a one-time, after-tax charge of $68 mil.; Closure shareholders will receive $27 for each outstanding share. The addition to the device unit closely follows J&J's purchase of Guidant in December...

You may also be interested in...



J&J Closure acquisition

Johnson & Johnson has completed its acquisition of Closure Medical, the firm announces June 3. The Band-Aid Liquid Bandage and Dermabond topical adhesive maker is being purchased for $370 mil., J&J said when announcing the merger in March (1"The Tan Sheet" March 7, 2005, In Brief)...

Anti-Tau For Alzheimer's In The Dock After Semorinemab Fail

Hopes that the Phase II TAURIEL trial could potentially validate the anti-tau antibody approach to treating Alzheimer's have been dashed as semorinemab did not meet its endpoints.

Indivior Reorganizing And Re-Investing In US Commercial Functions

Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel